BAUSCH AND LOMB INC Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for BAUSCH AND LOMB INC, and when can generic versions of BAUSCH AND LOMB INC drugs launch?
BAUSCH AND LOMB INC has fifteen approved drugs.
There are eight US patents protecting BAUSCH AND LOMB INC drugs.
There are one hundred and thirty-eight patent family members on BAUSCH AND LOMB INC drugs in twenty-seven countries and thirty-one supplementary protection certificates in thirteen countries.
Summary for BAUSCH AND LOMB INC
| International Patents: | 138 |
| US Patents: | 8 |
| Tradenames: | 16 |
| Ingredients: | 12 |
| NDAs: | 15 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for BAUSCH AND LOMB INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | LUMIFY | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 208144-001 | Dec 22, 2017 | OTC | Yes | Yes | 8,293,742 | See Plans and Pricing | See Plans and Pricing | ||||
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-002 | Nov 4, 1993 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
| Bausch And Lomb Inc | LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219-001 | Feb 22, 2019 | RX | Yes | Yes | 10,596,107 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Bausch And Lomb Inc | TIMOPTIC | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 018086-001 | Approved Prior to Jan 1, 1982 | AT1 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | 9,636,332 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAUSCH AND LOMB INC
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
International Patents for BAUSCH AND LOMB INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112016004054 | See Plans and Pricing |
| European Patent Office | 3417896 | See Plans and Pricing |
| Portugal | 2320911 | See Plans and Pricing |
| New Zealand | 701069 | See Plans and Pricing |
| Spain | 2371340 | See Plans and Pricing |
| Japan | 2013514985 | See Plans and Pricing |
| Canada | 2865593 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAUSCH AND LOMB INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1586316 | C 2011 004 | Romania | See Plans and Pricing | PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518 |
| 0509752 | C990041 | Netherlands | See Plans and Pricing | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
| 1631293 | 2014C/042 | Belgium | See Plans and Pricing | PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221 |
| 1631293 | C300683 | Netherlands | See Plans and Pricing | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 0957929 | CA 2006 00021 | Denmark | See Plans and Pricing | PRODUCT NAME: PEGAPTANIB, NATRIUM |
| 0509752 | 49/1999 | Austria | See Plans and Pricing | PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306 |
| 0957929 | 06C0021 | France | See Plans and Pricing | PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
